These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Malignant pheochromocytomas and paragangliomas - the importance of a multidisciplinary approach. Andersen KF; Altaf R; Krarup-Hansen A; Kromann-Andersen B; Horn T; Christensen NJ; Hendel HW Cancer Treat Rev; 2011 Apr; 37(2):111-9. PubMed ID: 20675056 [TBL] [Abstract][Full Text] [Related]
23. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261 [TBL] [Abstract][Full Text] [Related]
24. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy. Takano A; Oriuchi N; Tsushima Y; Taketomi-Takahashi A; Nakajima T; Arisaka Y; Higuchi T; Amanuma M; Endo K Ann Nucl Med; 2008 Jun; 22(5):395-401. PubMed ID: 18600417 [TBL] [Abstract][Full Text] [Related]
25. Integrated PET/MRI With 68Ga-DOTATATE and 18F-FDG in Pheochromocytomas and Paragangliomas: An Initial Study. Xu S; Pan Y; Zhou J; Ju H; Zhang Y Clin Nucl Med; 2022 Apr; 47(4):299-304. PubMed ID: 35143455 [TBL] [Abstract][Full Text] [Related]
26. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618 [TBL] [Abstract][Full Text] [Related]
28. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420 [TBL] [Abstract][Full Text] [Related]
29. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588 [TBL] [Abstract][Full Text] [Related]
30. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850 [TBL] [Abstract][Full Text] [Related]
31. Moving Beyond "Lumpology": PET/CT Imaging of Pheochromocytoma and Paraganglioma. Hofman MS; Hicks RJ Clin Cancer Res; 2015 Sep; 21(17):3815-7. PubMed ID: 26152741 [TBL] [Abstract][Full Text] [Related]
32. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions. Kornaczewski ER; Pointon OP; Burgess JR Clin Endocrinol (Oxf); 2016 Aug; 85(2):172-9. PubMed ID: 26776272 [TBL] [Abstract][Full Text] [Related]
33. [Diagnostic approach of pheochromocytomas and paragangliomas]. Gómez RM; Hernaiz M; de Miguel V; Aparicio LS; Marín MJ; Lupi S; Barontini M; Hipertens Riesgo Vasc; 2019; 36(1):34-43. PubMed ID: 30078655 [TBL] [Abstract][Full Text] [Related]
34. Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography. Michałowska I; Ćwikła JB; Pęczkowska M; Furmanek MI; Buscombe JR; Michalski W; Prejbisz A; Szperl M; Malinoc A; Moczulski D; Szutkowski Z; Kawecki A; Antoniewicz J; Pęczkowski P; Lewczuk A; Otto M; Cichocki A; Bednarek-Tupikowska G; Kabat M; Janaszek-Sitkowska H; Przybyłowska K; Janas J; Neumann HP; Januszewicz A Neuroendocrinology; 2015; 101(4):321-30. PubMed ID: 25791839 [TBL] [Abstract][Full Text] [Related]
35. Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. Nockel P; El Lakis M; Gaitanidis A; Merkel R; Patel D; Nilubol N; Prodanov T; Pacak K; Kebebew E Ann Surg; 2019 Apr; 269(4):741-747. PubMed ID: 29334561 [TBL] [Abstract][Full Text] [Related]
37. Clinical, Diagnostic, and Treatment Characteristics of Jha A; de Luna K; Balili CA; Millo C; Paraiso CA; Ling A; Gonzales MK; Viana B; Alrezk R; Adams KT; Tena I; Chen A; Neuzil J; Raygada M; Kebebew E; Taieb D; O'Dorisio MS; O'Dorisio T; Civelek AC; Stratakis CA; Mercado-Asis L; Pacak K Front Oncol; 2019; 9():53. PubMed ID: 30854332 [No Abstract] [Full Text] [Related]
38. Comparison of the 68Ga-DOTATATA PET/CT, FDG PET/CT, and MIBG SPECT/CT in the Evaluation of Suspected Primary Pheochromocytomas and Paragangliomas. Jing H; Li F; Wang L; Wang Z; Li W; Huo L; Zhang J Clin Nucl Med; 2017 Jul; 42(7):525-529. PubMed ID: 28481789 [TBL] [Abstract][Full Text] [Related]
39. Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma. Puar T; van Berkel A; Gotthardt M; Havekes B; Hermus AR; Lenders JW; van Marken Lichtenbelt WD; Xu Y; Brans B; Timmers HJ J Clin Endocrinol Metab; 2016 Jan; 101(1):224-32. PubMed ID: 26574955 [TBL] [Abstract][Full Text] [Related]